Commentary|Videos|August 3, 2023
Public Misunderstandings Around Clinical Trials
Author(s)Lisa Henderson
"What does the general public not understand the most about clinical trials?" is the question we posed to three industry professionals at DIA 2023.
Advertisement
"What does the general public not understand the most about clinical trials?" is the question we posed to three industry professionals. And their answers span only a few of the challenges that remain in patient education and knowledge about the clinical research enterprise.
In this video, Kenneth Getz, Executive Director and Professor, Tufts Center for the Study of Drug Development and Founder, Board Chair, CISCRP; Janice Chang, CEO of TransCelerate BioPharma, and Greg Ball, Safety Data Scientist and founder, ASAP Process Consulting present their views on the topic.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Data Quality as Foundational to Trial Modernization, CRAs Evolving to Strategic Site Partners, and 2026 Emerging Pharma Leaders Announced
2
Breaking the Efficacy Ceiling in IBD and Beyond
3
ACT Brief: Training Completion Versus Execution Readiness, AI Monitoring Agent Financial Value at Scale, and FDA Warning Letters and AI Oversight Gaps
4
Closing the Dead Time Gap in Clinical Data: Q&A with Raviv Pryluk, PhaseV
5